Posts tagged District of Delaware
IntelGenx film process does not infringe MonoSol patent

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a decision by the U.S. District Court for the District of Delaware determined that the process used to manufacture IntelGenx's and Par Pharmaceutical's buprenorphine/naloxone sublingual film product for the treatment of opiate addiction does not infringe MonoSol Rx U.S. Patent No. 8,900,497. 

Read More